Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

EGF receptor (EGFR) inhibition promotes a slow-twitch oxidative, over a fast-twitch, muscle phenotype.

Ciano M, Mantellato G, Connolly M, Paul-Clark M, Willis-Owen S, Moffatt MF, Cookson WOCM, Mitchell JA, Polkey MI, Hughes SM, Kemp PR, Natanek SA.

Sci Rep. 2019 Jun 25;9(1):9218. doi: 10.1038/s41598-019-45567-4.

2.

Sex differences in COPD-related quadriceps muscle dysfunction and fibre abnormalities.

Sharanya A, Ciano M, Withana S, Kemp PR, Polkey MI, Sathyapala SA.

Chron Respir Dis. 2019 Jan-Dec;16:1479973119843650. doi: 10.1177/1479973119843650.

3.

Quadriceps miR-542-3p and -5p are elevated in COPD and reduce function by inhibiting ribosomal and protein synthesis.

Farre-Garros R, Lee JY, Natanek SA, Connolly M, Sayer AA, Patel H, Cooper C, Polkey MI, Kemp PR.

J Appl Physiol (1985). 2019 Jun 1;126(6):1514-1524. doi: 10.1152/japplphysiol.00882.2018. Epub 2019 Jan 24.

4.

Muscle wasting in the presence of disease, why is it so variable?

Kemp PR, Griffiths M, Polkey MI.

Biol Rev Camb Philos Soc. 2019 Jun;94(3):1038-1055. doi: 10.1111/brv.12489. Epub 2018 Dec 26.

PMID:
30588725
5.

Growth/differentiation factor 15 causes TGFβ-activated kinase 1-dependent muscle atrophy in pulmonary arterial hypertension.

Garfield BE, Crosby A, Shao D, Yang P, Read C, Sawiak S, Moore S, Parfitt L, Harries C, Rice M, Paul R, Ormiston ML, Morrell NW, Polkey MI, Wort SJ, Kemp PR.

Thorax. 2019 Feb;74(2):164-176. doi: 10.1136/thoraxjnl-2017-211440. Epub 2018 Dec 15.

6.

COPD is accompanied by co-ordinated transcriptional perturbation in the quadriceps affecting the mitochondria and extracellular matrix.

Willis-Owen SAG, Thompson A, Kemp PR, Polkey MI, Cookson WOCM, Moffatt MF, Natanek SA.

Sci Rep. 2018 Aug 15;8(1):12165. doi: 10.1038/s41598-018-29789-6.

7.

miR-322-5p targets IGF-1 and is suppressed in the heart of rats with pulmonary hypertension.

Connolly M, Garfield BE, Crosby A, Morrell NW, Wort SJ, Kemp PR.

FEBS Open Bio. 2018 Jan 24;8(3):339-348. doi: 10.1002/2211-5463.12369. eCollection 2018 Mar.

8.

Leucine and ACE inhibitors as therapies for sarcopenia (LACE trial): study protocol for a randomised controlled trial.

Band MM, Sumukadas D, Struthers AD, Avenell A, Donnan PT, Kemp PR, Smith KT, Hume CL, Hapca A, Witham MD.

Trials. 2018 Jan 4;19(1):6. doi: 10.1186/s13063-017-2390-9.

9.

miR-424-5p reduces ribosomal RNA and protein synthesis in muscle wasting.

Connolly M, Paul R, Farre-Garros R, Natanek SA, Bloch S, Lee J, Lorenzo JP, Patel H, Cooper C, Sayer AA, Wort SJ, Griffiths M, Polkey MI, Kemp PR.

J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):400-416. doi: 10.1002/jcsm.12266. Epub 2017 Dec 7.

10.

miR-422a suppresses SMAD4 protein expression and promotes resistance to muscle loss.

Paul R, Lee J, Donaldson AV, Connolly M, Sharif M, Natanek SA, Rosendahl U, Polkey MI, Griffiths M, Kemp PR.

J Cachexia Sarcopenia Muscle. 2018 Feb;9(1):119-128. doi: 10.1002/jcsm.12236. Epub 2017 Oct 6.

11.

MicroRNA-542 Promotes Mitochondrial Dysfunction and SMAD Activity and Is Elevated in Intensive Care Unit-acquired Weakness.

Garros RF, Paul R, Connolly M, Lewis A, Garfield BE, Natanek SA, Bloch S, Mouly V, Griffiths MJ, Polkey MI, Kemp PR.

Am J Respir Crit Care Med. 2017 Dec 1;196(11):1422-1433. doi: 10.1164/rccm.201701-0101OC.

12.

Circulating miRNAs from imprinted genomic regions are associated with peripheral muscle strength in COPD patients.

Lee JY, Donaldson AV, Lewis A, Natanek SA, Polkey MI, Kemp PR.

Eur Respir J. 2017 Apr 26;49(4). pii: 1601881. doi: 10.1183/13993003.01881-2016. Print 2017 Apr. No abstract available.

13.

Muscle Regeneration after Critical Illness: Are Satellite Cells the Answer?

Polkey MI, Griffiths MJ, Kemp PR.

Am J Respir Crit Care Med. 2016 Oct 1;194(7):780-782. No abstract available.

14.

Using laser capture microdissection to study fiber specific signaling in locomotor muscle in COPD: A pilot study.

Mohan D, Lewis A, Patel MS, Curtis KJ, Lee JY, Hopkinson NS, Wilkinson IB, Kemp PR, Polkey MI.

Muscle Nerve. 2017 Jun;55(6):902-912. doi: 10.1002/mus.25423. Epub 2017 Feb 3.

15.

Increased expression of H19/miR-675 is associated with a low fat-free mass index in patients with COPD.

Lewis A, Lee JY, Donaldson AV, Natanek SA, Vaidyanathan S, Man WD, Hopkinson NS, Sayer AA, Patel HP, Cooper C, Syddall H, Polkey MI, Kemp PR.

J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):330-44. doi: 10.1002/jcsm.12078. Epub 2016 Jan 5.

16.

Growth differentiation factor-15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo.

Patel MS, Lee J, Baz M, Wells CE, Bloch S, Lewis A, Donaldson AV, Garfield BE, Hopkinson NS, Natanek A, Man WD, Wells DJ, Baker EH, Polkey MI, Kemp PR.

J Cachexia Sarcopenia Muscle. 2016 Sep;7(4):436-48. doi: 10.1002/jcsm.12096. Epub 2015 Dec 29.

17.

Klotho and smoking--An interplay influencing the skeletal muscle function deficits that occur in COPD.

Patel MS, Donaldson AV, Lewis A, Natanek SA, Lee JY, Andersson YM, Haji G, Jackson SG, Bolognese BJ, Foley JP, Podolin PL, Bruijnzeel PL, Hart N, Hopkinson NS, Man WD, Kemp PR, Polkey MI.

Respir Med. 2016 Apr;113:50-6. doi: 10.1016/j.rmed.2016.02.004. Epub 2016 Feb 15.

18.

FHL1 activates myostatin signalling in skeletal muscle and promotes atrophy.

Lee JY, Lori D, Wells DJ, Kemp PR.

FEBS Open Bio. 2015 Sep 1;5:753-62. doi: 10.1016/j.fob.2015.08.011. eCollection 2015.

19.

MiR-181a: a potential biomarker of acute muscle wasting following elective high-risk cardiothoracic surgery.

Bloch SA, Donaldson AV, Lewis A, Banya WA, Polkey MI, Griffiths MJ, Kemp PR.

Crit Care. 2015 Apr 7;19:147. doi: 10.1186/s13054-015-0853-5.

20.

Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs.

Bloch SA, Lee JY, Syburra T, Rosendahl U, Griffiths MJ, Kemp PR, Polkey MI.

Thorax. 2015 Mar;70(3):219-28. doi: 10.1136/thoraxjnl-2014-206225. Epub 2014 Dec 16.

21.

Skeletal muscle adiposity is associated with physical activity, exercise capacity and fibre shift in COPD.

Maddocks M, Shrikrishna D, Vitoriano S, Natanek SA, Tanner RJ, Hart N, Kemp PR, Moxham J, Polkey MI, Hopkinson NS.

Eur Respir J. 2014 Nov;44(5):1188-98. doi: 10.1183/09031936.00066414. Epub 2014 Jul 3.

22.

A randomized controlled trial of angiotensin-converting enzyme inhibition for skeletal muscle dysfunction in COPD.

Shrikrishna D, Tanner RJ, Lee JY, Natanek A, Lewis A, Murphy PB, Hart N, Moxham J, Montgomery HE, Kemp PR, Polkey MI, Hopkinson NS.

Chest. 2014 Oct;146(4):932-940. doi: 10.1378/chest.13-2483.

23.

Phenotypic characteristics associated with reduced short physical performance battery score in COPD.

Patel MS, Mohan D, Andersson YM, Baz M, Samantha Kon SC, Canavan JL, Jackson SG, Clark AL, Hopkinson NS, Natanek SA, Kemp PR, Bruijnzeel PLB, Man WD, Polkey MI.

Chest. 2014 May;145(5):1016-1024. doi: 10.1378/chest.13-1398.

PMID:
24337162
24.

MuRF-1 and atrogin-1 protein expression and quadriceps fiber size and muscle mass in stable patients with COPD.

Natanek SA, Riddoch-Contreras J, Marsh GS, Hopkinson NS, Moxham J, Man WD, Kemp PR, Polkey MI.

COPD. 2013 Oct;10(5):618-24. doi: 10.3109/15412555.2013.781577. Epub 2013 Jul 11.

25.

Increased skeletal muscle-specific microRNA in the blood of patients with COPD.

Donaldson A, Natanek SA, Lewis A, Man WD, Hopkinson NS, Polkey MI, Kemp PR.

Thorax. 2013 Dec;68(12):1140-9. doi: 10.1136/thoraxjnl-2012-203129. Epub 2013 Jun 28.

26.

Heterogeneity of quadriceps muscle phenotype in chronic obstructive pulmonary disease (Copd); implications for stratified medicine?

Natanek SA, Gosker HR, Slot IG, Marsh GS, Hopkinson NS, Man WD, Tal-Singer R, Moxham J, Kemp PR, Schols AM, Polkey MI.

Muscle Nerve. 2013 Oct;48(4):488-97. doi: 10.1002/mus.23784. Epub 2013 Aug 27.

27.
28.

Pathways associated with reduced quadriceps oxidative fibres and endurance in COPD.

Natanek SA, Gosker HR, Slot IG, Marsh GS, Hopkinson NS, Moxham J, Kemp PR, Schols AM, Polkey MI.

Eur Respir J. 2013 Jun;41(6):1275-83. doi: 10.1183/09031936.00098412. Epub 2012 Dec 20.

29.

Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease.

Shrikrishna D, Astin R, Kemp PR, Hopkinson NS.

Clin Sci (Lond). 2012 Oct;123(8):487-98. doi: 10.1042/CS20120081. Review.

PMID:
22757959
30.

Quadriceps wasting and physical inactivity in patients with COPD.

Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, Walsh SL, Bloch SA, Sidhu PS, Hart N, Kemp PR, Moxham J, Polkey MI, Hopkinson NS.

Eur Respir J. 2012 Nov;40(5):1115-22. doi: 10.1183/09031936.00170111. Epub 2012 Feb 23.

31.

Myostatin induces autophagy in skeletal muscle in vitro.

Lee JY, Hopkinson NS, Kemp PR.

Biochem Biophys Res Commun. 2011 Dec 2;415(4):632-6. doi: 10.1016/j.bbrc.2011.10.124. Epub 2011 Nov 2.

PMID:
22079631
32.

Downregulation of the serum response factor/miR-1 axis in the quadriceps of patients with COPD.

Lewis A, Riddoch-Contreras J, Natanek SA, Donaldson A, Man WD, Moxham J, Hopkinson NS, Polkey MI, Kemp PR.

Thorax. 2012 Jan;67(1):26-34. doi: 10.1136/thoraxjnl-2011-200309. Epub 2011 Oct 13.

33.

The health implications of birth by Caesarean section.

Hyde MJ, Mostyn A, Modi N, Kemp PR.

Biol Rev Camb Philos Soc. 2012 Feb;87(1):229-43. doi: 10.1111/j.1469-185X.2011.00195.x. Epub 2011 Aug 5. Review.

PMID:
21815988
34.

Yin Yang 1 expression and localisation in quadriceps muscle in COPD.

Natanek SA, Riddoch-Contreras J, Marsh GS, Hopkinson NS, Man WD, Moxham J, Polkey MI, Kemp PR.

Arch Bronconeumol. 2011 Jun;47(6):296-302. doi: 10.1016/j.arbres.2011.02.015. Epub 2011 May 11. English, Spanish.

35.

Do miniaturized extracorporeal circuits confer significant clinical benefit without compromising safety? A meta-analysis of randomized controlled trials.

Harling L, Warren OJ, Martin A, Kemp PR, Evans PC, Darzi A, Athanasiou T.

ASAIO J. 2011 May-Jun;57(3):141-51. doi: 10.1097/MAT.0b013e318209d63b.

PMID:
21266906
36.

Quadriceps myostatin expression in COPD.

Man WD, Natanek SA, Riddoch-Contreras J, Lewis A, Marsh GS, Kemp PR, Polkey MI.

Eur Respir J. 2010 Sep;36(3):686-8. doi: 10.1183/09031936.00032510. No abstract available.

37.

Perfusion of veins at arterial pressure increases the expression of KLF5 and cell cycle genes in smooth muscle cells.

Amirak E, Zakkar M, Evans PC, Kemp PR.

Biochem Biophys Res Commun. 2010 Jan 1;391(1):818-23. doi: 10.1016/j.bbrc.2009.11.145. Epub 2009 Dec 2.

38.

Delivery by Caesarean section, rather than vaginal delivery, promotes hepatic steatosis in piglets.

Hyde MJ, Griffin JL, Herrera E, Byrne CD, Clarke L, Kemp PR.

Clin Sci (Lond). 2009 Oct 2;118(1):47-59. doi: 10.1042/CS20090169.

PMID:
19445654
39.

Splenomegaly and modified erythropoiesis in KLF13-/- mice.

Gordon AR, Outram SV, Keramatipour M, Goddard CA, Colledge WH, Metcalfe JC, Hager-Theodorides AL, Crompton T, Kemp PR.

J Biol Chem. 2008 May 2;283(18):11897-904. doi: 10.1074/jbc.M709569200. Epub 2008 Feb 19.

40.
41.

Visualization of alternative splicing in vivo.

Kemp PR, Ellis PD, Smith CW.

Methods. 2005 Dec;37(4):360-7.

PMID:
16314265
42.

Overexpression of a family of RPEL proteins modifies cell shape.

Favot L, Gillingwater M, Scott C, Kemp PR.

FEBS Lett. 2005 Jan 3;579(1):100-4.

43.

Modifying the 'pulse-reserve' paradigm for deserts of North America: precipitation pulses, soil water, and plant responses.

Reynolds JF, Kemp PR, Ogle K, Fernández RJ.

Oecologia. 2004 Oct;141(2):194-210. Epub 2004 Mar 20.

PMID:
15042457
44.

Adhesion of endothelial cells to NOV is mediated by the integrins alphavbeta3 and alpha5beta1.

Ellis PD, Metcalfe JC, Hyvönen M, Kemp PR.

J Vasc Res. 2003 May-Jun;40(3):234-43.

PMID:
12902636
45.
46.

A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer.

Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, Pharoah PD, Easton DF, Ponder BA, Metcalfe JC.

Cancer Res. 2003 May 15;63(10):2610-5.

47.

Increased actin polymerization reduces the inhibition of serum response factor activity by Yin Yang 1.

Ellis PD, Martin KM, Rickman C, Metcalfe JC, Kemp PR.

Biochem J. 2002 Jun 1;364(Pt 2):547-54.

48.

Effects of premature stimulation on HERG K(+) channels.

Lu Y, Mahaut-Smith MP, Varghese A, Huang CL, Kemp PR, Vandenberg JI.

J Physiol. 2001 Dec 15;537(Pt 3):843-51.

49.

Expression of Klf9 and Klf13 in mouse development.

Martin KM, Metcalfe JC, Kemp PR.

Mech Dev. 2001 May;103(1-2):149-51.

50.

Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.

Lücke CD, Philpott A, Metcalfe JC, Thompson AM, Hughes-Davies L, Kemp PR, Hesketh R.

Cancer Res. 2001 Jan 15;61(2):482-5.

Supplemental Content

Support Center